September 13, 2024

VIA EDGAR AND EMAIL

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Attn: Tamika Sheppard

Re:	Spyre Therapeutics, Inc.
	Registration Statement on Form S-3
	Filed September 6, 2024
	File No. 333-281975

To Whom it May Concern:

Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended (the “Act”), Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-3 filed by the Company be accelerated to 4:15 p.m., Eastern Time, on September 18, 2024 or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Branden Berns at (415) 393-4631.

Very truly yours,
SPYRE THERAPEUTICS, INC.
By:	/s/ Cameron Turtle
Name:	Cameron Turtle
Title:	Chief Executive Officer

cc:	Scott Burrows, Spyre Therapeutics, Inc.
	Heidy King-Jones, Spyre Therapeutics, Inc.
	Ryan A. Murr, Gibson, Dunn & Crutcher LLP
	Branden C. Berns, Gibson, Dunn & Crutcher LLP